FDA Accepts Supplement for VABYSMO by Genentech
The FDA has accepted a supplemental application for VABYSMO (BLA761235) from Genentech.
Therapeutic Area
Therapeutic area intelligence for Anti-VEGF with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.